John Finlayson grew up in New Jersey, Delaware, Virginia, and Ohio. He completed high school in 1945 at the age of 15 and went to college in Ohio where he was a pre-med student. Instead of going to medical school, however, he completed a masters (1955) and Ph.D. (1957) in biochemistry at University of Wisconsin-Madison. He was able to defer the military draft an extra year to do a post-doctoral fellowship at the Institute of Radiophysics in Sweden. Finlayson returned to the United States in the fall of 1958 and received a commission in the Public Health Service (PHS). He was assigned to the Laboratory of Blood and Blood Products in the National Institutes of Health (NIH) Division of Biologics Standards (DBS), where he carried out his two years of service. After 2.5 years, he went into inactive reserve for the PHS, staying in the same job at the Coagulation Section of the Laboratory of Blood and Blood Products as a civil service. He then continued to perform his duties when his section came under the jurisdiction of the FDA in 1972. Finlayson researched plasma derivatives most of his career, especially as related to hemophilia, a medical condition in which the blood cannot clot properly. Finlayson worked on Factor VIII, an essential blood-clotting protein, sometimes called anti-hemophilic factor (not licensed until 1966). |